Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions

References

• Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. (2002). Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685–91.
   PubMed Web of Science ®Google Scholar
• Bahadur N, Leathart JB, Mutch E, Stermel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579–89.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Clarke SE, Chenery RJ. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424–32.
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal Biochem 72:248–54.
   PubMed Web of Science ®Google Scholar
• Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. (2003). Drug interaction of paclitaxel metabolism in human liver microsomes. J Chemotherapy 3:266–74.
   Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607.
   PubMedGoogle Scholar
• Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349–55.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. (2006). Drug interaction studies—study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/cder/guidance/6695dft.pdf. Accessed on March 14, 2006.
   Google Scholar
• Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman’s The pharmacological basis of therapeutics. New York, USA: McGraw-Hill Professional.
   Google Scholar
• Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suauki S, Satoh T, Shinoda S, Kataoka H, Narimatsu S. (2002). Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem Pharmacol 64:1101–10.
   PubMed Web of Science ®Google Scholar
• Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori  N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami  N, Katoch M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. (2005). Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K274R, and K383N, found in a Japanese population. Drug Metab Dispos 33:630–6.
   PubMed Web of Science ®Google Scholar
• Ho SN, Hunt HD, Horton RM, Pullen JK, Peras LR. (1989). Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51–9.
   PubMed Web of Science ®Google Scholar
• Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher C, Rettie  AE, Tracy TS. (2005). CYP2C9 genotype-dependent effects on in vitro drug–drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68:644–54.
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in-vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86.
   PubMed Web of Science ®Google Scholar
• Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh  Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:53–60.
   Google Scholar
• Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharma Res 17:336–43.
   Google Scholar
• Krippendorff BF, Lienau P, Reichel A, Huisinga W. (2007) Optimizing classification of drug–drug interaction potential for CYP450 iso-enzymes inhibition assays in early drug discovery. J Biomol Screen 12:92–9.
   PubMedGoogle Scholar
• Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. (2006). CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966–75.
   PubMed Web of Science ®Google Scholar
• Loi CM, Young M, Randinitis E, Vassos A, Koup JR. (1999). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91–104.
   PubMed Web of Science ®Google Scholar
• Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, Mansuy D. (2004). Analysis of human cytochrome P450 2C8 substrate specific using a substrate pharmacophore and site-direct mutants. Biochemistry 43:15379–92.
   PubMed Web of Science ®Google Scholar
• Muthiah YD, Lee WL, The LK, Ong CE, Ismail R. (2005). Genetics polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J Clin Pharm Ther 30:487–90.
   PubMedGoogle Scholar
• Niemi M, Backman JT, Granfors JL, Laitila J, Neuvonen M, Neuvonen PJ. (2003a). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46:1319–23.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. (2003b). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 74:347–51.
   Google Scholar
• Omura T, Sato R. (1964). Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–8.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Vakkalagadda GR, Leeder JS. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochrome P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170–9.
   PubMed Web of Science ®Google Scholar
• Projean D, Morin PE, Tu TM, Ducharme J. (2003). Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 33:841–54.
   PubMed Web of Science ®Google Scholar
• Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. (1994). Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543–6.
   PubMed Web of Science ®Google Scholar
• Singh R, Ting JG, Pan Y, The LK, Ismail R, Ong CE. (2008). Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23:165–74.
   PubMed Web of Science ®Google Scholar
• Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. (1995). Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566–75.
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341–52.
   PubMed Web of Science ®Google Scholar
• Tuker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Br J Clin Pharmacol 70:103–14.
   Google Scholar
• Walsky RL, Gaman EA, Obach RT. (2005). Examination of 209 drugs for inhibition of cytochrome P4502C8. J Clin Pharmacol 45:68–78.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. (2000). In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 30:61–70.
   PubMed Web of Science ®Google Scholar